 Fabry Disease
"Fabry Disease" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An X-linked inherited metabolic disease caused by a deficiency of lysosomal ALPHA-GALACTOSIDASE A. It is characterized by intralysosomal accumulation of globotriaosylceramide and other GLYCOSPHINGOLIPIDS in blood vessels throughout the body leading to multi-system complications including renal, cardiac, cerebrovascular, and skin disorders.
| Descriptor ID |
D000795
|
| MeSH Number(s) |
C10.228.140.163.100.435.825.200 C10.228.140.300.275.374 C14.907.253.329.374 C16.320.322.124 C16.320.565.189.435.825.200 C16.320.565.398.641.803.300 C16.320.565.595.554.825.200 C18.452.132.100.435.825.200 C18.452.584.687.803.300 C18.452.648.189.435.825.200 C18.452.648.398.641.803.300 C18.452.648.595.554.825.200
|
| Concept/Terms |
Fabry Disease- Fabry Disease
- Disease, Fabry
- alpha-Galactosidase A Deficiency Disease
- alpha Galactosidase A Deficiency Disease
- Anderson-Fabry Disease
- Anderson Fabry Disease
- Hereditary Dystopic Lipidosis
- Dystopic Lipidoses, Hereditary
- Dystopic Lipidosis, Hereditary
- Hereditary Dystopic Lipidoses
- Lipidoses, Hereditary Dystopic
- Lipidosis, Hereditary Dystopic
- Angiokeratoma, Diffuse
- Angiokeratomas, Diffuse
- Diffuse Angiokeratoma
- Diffuse Angiokeratomas
- Ceramide Trihexosidase Deficiency
- Ceramide Trihexosidase Deficiencies
- Deficiencies, Ceramide Trihexosidase
- Deficiency, Ceramide Trihexosidase
- Trihexosidase Deficiencies, Ceramide
- Trihexosidase Deficiency, Ceramide
- Fabry's Disease
- Fabrys Disease
- alpha-Galactosidase A Deficiency
- Deficiencies, alpha-Galactosidase A
- Deficiency, alpha-Galactosidase A
- alpha Galactosidase A Deficiency
- alpha-Galactosidase A Deficiencies
- Angiokeratoma Corporis Diffusum
|
Below are MeSH descriptors whose meaning is more general than "Fabry Disease".
- Diseases [C]
- Nervous System Diseases [C10]
- Central Nervous System Diseases [C10.228]
- Brain Diseases [C10.228.140]
- Brain Diseases, Metabolic [C10.228.140.163]
- Brain Diseases, Metabolic, Inborn [C10.228.140.163.100]
- Lysosomal Storage Diseases, Nervous System [C10.228.140.163.100.435]
- Sphingolipidoses [C10.228.140.163.100.435.825]
- Fabry Disease [C10.228.140.163.100.435.825.200]
- Cerebrovascular Disorders [C10.228.140.300]
- Cerebral Small Vessel Diseases [C10.228.140.300.275]
- Fabry Disease [C10.228.140.300.275.374]
- Cardiovascular Diseases [C14]
- Vascular Diseases [C14.907]
- Cerebrovascular Disorders [C14.907.253]
- Cerebral Small Vessel Diseases [C14.907.253.329]
- Fabry Disease [C14.907.253.329.374]
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
- Genetic Diseases, Inborn [C16.320]
- Genetic Diseases, X-Linked [C16.320.322]
- Fabry Disease [C16.320.322.124]
- Metabolism, Inborn Errors [C16.320.565]
- Brain Diseases, Metabolic, Inborn [C16.320.565.189]
- Lysosomal Storage Diseases, Nervous System [C16.320.565.189.435]
- Sphingolipidoses [C16.320.565.189.435.825]
- Fabry Disease [C16.320.565.189.435.825.200]
- Lipid Metabolism, Inborn Errors [C16.320.565.398]
- Lipidoses [C16.320.565.398.641]
- Sphingolipidoses [C16.320.565.398.641.803]
- Fabry Disease [C16.320.565.398.641.803.300]
- Lysosomal Storage Diseases [C16.320.565.595]
- Lysosomal Storage Diseases, Nervous System [C16.320.565.595.554]
- Sphingolipidoses [C16.320.565.595.554.825]
- Fabry Disease [C16.320.565.595.554.825.200]
- Nutritional and Metabolic Diseases [C18]
- Metabolic Diseases [C18.452]
- Brain Diseases, Metabolic [C18.452.132]
- Brain Diseases, Metabolic, Inborn [C18.452.132.100]
- Lysosomal Storage Diseases, Nervous System [C18.452.132.100.435]
- Sphingolipidoses [C18.452.132.100.435.825]
- Fabry Disease [C18.452.132.100.435.825.200]
- Lipid Metabolism Disorders [C18.452.584]
- Lipidoses [C18.452.584.687]
- Sphingolipidoses [C18.452.584.687.803]
- Fabry Disease [C18.452.584.687.803.300]
- Metabolism, Inborn Errors [C18.452.648]
- Brain Diseases, Metabolic, Inborn [C18.452.648.189]
- Lysosomal Storage Diseases, Nervous System [C18.452.648.189.435]
- Sphingolipidoses [C18.452.648.189.435.825]
- Fabry Disease [C18.452.648.189.435.825.200]
- Lipid Metabolism, Inborn Errors [C18.452.648.398]
- Lipidoses [C18.452.648.398.641]
- Sphingolipidoses [C18.452.648.398.641.803]
- Fabry Disease [C18.452.648.398.641.803.300]
- Lysosomal Storage Diseases [C18.452.648.595]
- Lysosomal Storage Diseases, Nervous System [C18.452.648.595.554]
- Sphingolipidoses [C18.452.648.595.554.825]
- Fabry Disease [C18.452.648.595.554.825.200]
Below are MeSH descriptors whose meaning is more specific than "Fabry Disease".
This graph shows the total number of publications written about "Fabry Disease" by people in UAMS Profiles by year, and whether "Fabry Disease" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2022 | 1 | 0 | 1 | | 2019 | 1 | 0 | 1 | | 2009 | 1 | 0 | 1 | | 2008 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Fabry Disease" by people in Profiles over the past ten years.
-
Powell AW, Wittekind SG, Mays WA, Lang SM, Knilans TK, Prada CE, Hopkin RJ, Chin C. Arrhythmia Burden and Heart Rate Response During Exercise in Anderson-Fabry Disease. Tex Heart Inst J. 2022 09 01; 49(5).
-
Sheng S, Wu L, Nalleballe K, Sharma R, Brown A, Ranabothu S, Kapoor N, Onteddu S. Fabry's disease and stroke: Effectiveness of enzyme replacement therapy (ERT) in stroke prevention, a review with meta-analysis. J Clin Neurosci. 2019 Jul; 65:83-86.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|